Vermillion Shares Soar on Positive OVA1, Imaging Data | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Positive data presented on Vermillion's OVA1 ovarian cancer test sent the company's stock up almost 27 percent in mid-afternoon trading today.

With less than two hours left to the trading day, Vermillion's shares were trading at $3.10 and went as high as $3.50 earlier in the day. More than 1.1 million shares traded hands, a greater-than-seven-fold increase from the three-month average daily volume of 152,623.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.